Pioneering

Gene Therapy Solutions

Who we are

Since 1987, VJ Technologies (VJT) has been a pioneering technology firm designing and engineering x-ray technology, software, and products to tackle some of the world’s most challenging problems.

From becoming the de facto standard for inspection of 155mm munitions, to classification and remediation of legacy nuclear waste, to powering the latest generation of handheld baggage scanners, VJT’s innovations have touched and affected billions of lives on the planet.

VJT’s most recent venture, IITPL, has become the top cardiac cath lab provider in India. Within 4 years, it has developed and deployed over 500 units (to-date) of the most-award winning cath lab in the world. Most importantly, IITPL provides industry-leading imaging and diagnostic capabilities at cost-effective prices, democratizing access to cardiac care. 

Following in these footsteps, VJT’s newest venture is VJ Biosciences (VJ Bio). VJ Bio is a wholly owned subsidiary of VJT, focused on building an ecosystem to develop novel, safer, more affordable, and accessible gene therapy products.

Led by an experienced team of world renown scientists, partnered with industry leaders, backed by a company with a strong pedigree and a demonstrated story of success, VJ Bio is well-positioned to literally redefine the boundaries of human health. 

VJ Bio has these four areas that are interconnected and yet distinct from each other: diagnostics; therapeutics; biomanufacturing; and agricultural biotechnology. Products and technologies in these areas are being developed in-house as well as through external collaborations and partnerships. This will enable the creation of an ecosystem that will greatly augment development of these critical next generation technologies.

The four pillars are laid out below: 

  • Diagnostics

  • Therapeutics

  • Biomanufacturing

  • Agricultural Biotechnology

Diagnostic tests have proliferated at hospitals and clinics but lack the portability and specificity to make them relevant where they are most needed. Current tests often rely on detecting protein markers, which are less specific than detecting nucleic acid sequences. Nucleic acid-based tests are highly accurate but require specialized instruments and trained operators, limiting their use in such scenarios. Leveraging the CRISPR-Cas and microfluidics technologies, VJ Bio is developing fully integrated point-of-need testing (PoNT) products / instruments that are portable and easily accessible in remote areas. These PoNT products have broad applications in infectious diseases, cancer monitoring, inherited diseases, and veterinary pathogens surveillance. 

In addition to next generation viral and nonviral gene therapy vectors, VJ Bio is developing optimized payloads for treatment of genetic and pathway diseases. VJ Bio also aims to develop cell therapies in setting of CAR-T and iPSC derived cells for treatment of tumors and diseases requiring regenerative therapeutics. VJ Bio will also focus on the development of gene-editing tools to repair mutations in a variety of genetic diseases. 

In addition to the development of therapeutics and diagnostics, VJ Bio also has a core area of focus on biomanufacturing. Specifically, VJ Bio’s goal is to develop optimized end-to-end processes to manufacture a variety of biologics. Based on the extensive experience of the team, VJ Bio is developing proprietary processes and technologies that will enable rapid prototyping with flexibility and be able to scale up for highly efficient and cost-effective production of various biologics of interest. 

Another exciting area of development and application of gene editing is in the field of agriculture. VJ Bio will be working on adapting and deploying gene editing of plants of commercial interests for desired characteristics such as higher yield, increased nutritional value, and disease resistance. 

Get in Touch

Fill out the form and we’ll reach back out as soon as possible.